Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited said on Nov, 25 2025 that its Xinxin Pharmaceutical Plant has obtained a Drug Registration Certificate from China’s National Medical Products Administration for Loxoprofen Sodium Cataplasms, a topical analgesic patch.

The Class 4 chemical drug, filed under registration number H20255958 and valid until Nov, 17 2030, will be manufactured by Beijing Baiao Pharmaceutical Co., Ltd.

Indicated for inflammation and pain associated with osteoarthritis, muscle pain and post-traumatic swelling, the reference product generated nationwide sales of more than RMB1.7 billion in 2024 and over RMB980 million in the first half of 2025, according to Menet data.

The company has invested about RMB37.88 million in the project and said the approval marks its first modern gel-type cataplasm to pass quality-and-efficacy consistency evaluation. While the drug broadens its transdermal delivery portfolio, the firm does not expect a material near-term financial impact and advised investors to exercise caution.